{5-fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid | 851723-80-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: {5-fluoro-2-methyl-3-[1-(4-trifluoromethyl-phenyl)-ethyl]-indol-1-yl}-acetic acid
• 英文别名: 2-[5-fluoro-2-methyl-3-[1-[4-(trifluoromethyl)phenyl]ethyl]indol-1-yl]acetic Acid
• CAS: 851723-80-3
• 化学式: C₂₀H₁₇F₄NO₂
• 分子量: 379.354
• InChiKey: SFESJDVHISLSIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ESTERS D'ACIDE ACÉTIQUE (INDOL-1-YL) 3-SUBSTITUÉ
  申请人：ATOPIX THERAPEUTICS LTD

  公开号：WO2015092372A1

  公开（公告）日：2015-06-25

  The invention relates to an industrial scale process for the preparation of a compound of general formula (I): (Formula (I)) wherein R1, R2and R3are as defined herein. The process comprises reacting compounds of general formulae (II) and (III): (formulae (II), (III)) in the presence of a Lewis acid followed by a reduction with triethylsilane.

  本发明涉及一种工业规模的制备通式（I）化合物的过程：（通式（I）），其中R1，R2和R3如定义所述。该过程包括在路易斯酸存在下反应通式（II）和（III）的化合物：（通式（II），（III）），然后用三乙基硅烷还原。
• [EN] USE OF CRTH2 ANTAGONIST COMPOUNDS IN THERAPY<br/>[FR] UTILISATION DE COMPOSÉS ANTAGONISTES DE CRTH2 EN THÉRAPIE
  申请人：OXAGEN LTD

  公开号：WO2005044260A1

  公开（公告）日：2005-05-19

  Compounds of general formula (I) wherein R1, R2 , R3 and R4 are independently hydrogen, halo,C1-C6 alkyl, -O(C1-C6 alkyl), -CON(R11)2 , -SO11, -SO2R11, -SO2N(R11)2, -N(R11)2, -NR11COR11, -CO2R11, -COR11, -SR11, -OH, -NO2 or -CN; each R11 is independently hydrogen or C1 -C6 alkyl; R5 and R6 are each independently hydrogen, or C1-C6 alkyl or together with the carbon atom to which they are attached forrn a C3-C7 cycloalkyl group; R7 is hydrogen or C1-C6 alkyl; R8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C1-C6 alkyl, -O(C1-C6)alkyl, -CON(R11)2, -SOR11, -SO2R11 , -SO2N(R11)2, -N(R11)2, -NR11COR11, -CO2R11, -COR11, -SR11, -OH, -NO2 or -CN; wherein R11 is as defined above; R9 is hydrogen, or C1-C6 alkyl; provided that: R8 is not phenyl substituted with -COOH; when any two of R1, R2 , R3 and R4 are hydrogen, neither of the other two of R1, R2 , R3 and R4 is C3-C6 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in the preparation of pharmaceuticals for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  通式（I）的化合物，其中R1、R2、R3和R4分别独立地为氢、卤素、C1-C6烷基、-O(C1-C6烷基)、-CON(R11)2、-SO11、-SO2R11、-SO2N(R11)2、-N(R11)2、-NR11COR11、-CO2R11、-COR11、-SR11、-OH、-NO2或-CN；每个R11独立地为氢或C1-C6烷基；R5和R6分别独立地为氢，或C1-C6烷基，或与其连接的碳原子一起形成C3-C7环烷基基团；R7为氢或C1-C6烷基；R8为芳香基，可选地取代一个或多个卤素、C1-C6烷基、-O(C1-C6)烷基、-CON(R11)2、-SOR11、-SO2R11、-SO2N(R11)2、-N(R11)2、-NR11COR11、-CO2R11、-COR11、-SR11、-OH、- 或-CN的取代基；其中R11如上定义；R9为氢或C1-C6烷基；但是：R8不是取代有-COOH的苯基；当R1、R2、R3和R4中的任意两个为氢时，其余两个中的任何一个不是C3-C6烷基；以及它们的药学上可接受的盐、水合物、溶剂化合物或前药在制备用于治疗过敏疾病如哮喘、过敏性鼻炎和特应性皮炎的药物中是有用的。
• Use of CRTH2 antagonist compounds in therapy
  申请人：Oxagen Limited

  公开号：EP2060258A1

  公开（公告）日：2009-05-20

  Compounds of general formula (I) wherein R1, R2, R3 and R4 are independently hydrogen, halo, C1-C6 alkyl, -O(C1-C6 alkyl), -CON(R11)2 , -SO11, -SO2R11, - SO2N(R11)2, -N(R11)2, -NR11COR11, -CO2R11, -COR11, -SR11, -OH, -NO2 or -CN; each R11 is independently hydrogen or C1-C6 alkyl; R5 and R6 are each independently hydrogen, or C1-C6 alkyl or together with the carbon atom to which they are attached form a C3-C7 cycloalkyl group; R7 is hydrogen or C1-C6 alkyl; R8 is an aromatic moiety optionally substituted with one or more substituents selected from halo, C1-C6 alkyl, -O(C1-C6)alkyl, -CON(R11)2, -SOR11, -SO2R11, -SO2N(R11)2, -N(R11)2, - NR11COR11, -CO2R11, -COR11, -SR11, -OH, -NO2 or -CN; wherein R11 is as defined above; R9 is hydrogen, or C1-C6 alkyl; provided that: R8 is not phenyl substituted with -COOH; when any two of R1, R2, R3 and R4 are hydrogen, neither of the other two of R1, R2, R3 and R4 is C3-C6 alkyl; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in the preparation of pharmaceuticals for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

  通式 (I) 的化合物 其中 R1、R2、R3 和 R4 独立地为氢、卤素、C1-C6 烷基、-O(C1-C6 烷基)、-CON(R11)2、-SO11、-SO2R11、-SO2N(R11)2、-N(R11)2、-NR11COR11、-CO2R11、-COR11、-SR11、-OH、-NO2 或-CN；每个 R11 独立地为氢或 C1-C6 烷基； R5 和 R6 各自独立地为氢或 C1-C6 烷基，或与所连接的碳原子一起形成 C3-C7 环烷基；R7 是氢或 C1-C6 烷基； R8 是芳香族分子，可任选被一个或多个取代基取代，这些取代基选自卤代、C1-C6 烷基、-O(C1-C6)烷基、-CON(R11)2、-SOR11、-SO2R11、-SO2N(R11)2、-N(R11)2、-NR11COR11、-CO2R11、-COR11、-SR11、-OH、- 或-CN；其中 R11 如上定义； R9 是氢或 C1-C6 烷基；条件是R8不是被-COOH取代的苯基；当R1、R2、R3和R4中的任意两个是氢时，R1、R2、R3和R4中的另外两个都不是C3-C6烷基；它们的药学上可接受的盐、水合物、溶液、络合物或原药可用于制备治疗过敏性疾病如哮喘、过敏性鼻炎和特应性皮炎的药物。
• Treatment of CRTH2-mediated diseases and conditions
  申请人：Middlemiss David

  公开号：US20050119268A1

  公开（公告）日：2005-06-02

  The present invention provides indole derivatives that antagonize prostaglandin D 2 , and that can be used to treat inflammatory diseases mediated by prostaglandin D 2 .

  本发明提供了可拮抗前列腺素 D 2 2 介导的炎症性疾病的吲哚衍生物。 2 .
• UTILISATION DE COMPOSES DE TYPE RETINOIDES EN TANT QU'AGENTS ANTI-BACTERIENS CONTRE STAPHYLOCOCCUS AUREUS
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：EP1255543B1

  公开（公告）日：2010-09-01